Our objective was to identify risk factors predictive of severe disease in hospitalised patients. Chatacteristics associated with poor outcome in this population remain unclear. University of Strasbourg - Department of Infectious and Tropical Diseases More.īackground: In March 2020, the World Health Organization declared Europe as the new epicentre of the coronavirus disease 2019 (COVID-19) pandemic. Groupe Hospitalier de la Région Mulhouse Sud-Alsace François Danion University of Strasbourg - Department of Infectious and Tropical Diseases Olivier Hinschberger University of Strasbourg - Hôpitaux Universitaires de Strasbourg Yves Hansmann University of Strasbourg - Hôpitaux Universitaires de Strasbourg Nicolas Meyer University of Strasbourg - Department of Infectious and Tropical Diseases Floriane Gallais University of Strasbourg - Hôpitaux Universitaires de Strasbourg Nicolas Lefebvre University of Strasbourg - Hôpitaux Universitaires de Strasbourg Loïc Kassegne University of Strasbourg - Hôpitaux Universitaires de Strasbourg Valentin Greigert Groupe Hospitalier de la Région Mulhouse Sud-Alsace Raphael Clere-Jehl University of Strasbourg - Department of Infectious and Tropical Diseases Valentin Pointurier University of Strasbourg - Department of Infectious and Tropical Diseases Yves-Jean Zhu University of Strasbourg - Department of Infectious and Tropical Diseases Antonin Hugerot Groupe Hospitalier de la Région Mulhouse Sud-Alsace Yvon Ruch Groupe Hospitalier de la Région Mulhouse Sud-Alsace Benjamin Dervieux Les Hôpitaux Universitaires de Strasbourg - Public Health Joy Mootien University of Strasbourg - Department of Infectious and Tropical Diseases Thibaut Fabacher University of Strasbourg - Department of Infectious and Tropical Diseases Coralie Le Hyaric See all articles by Charlotte Kaeuffer Charlotte Kaeuffer
LOIC LEFEBVRE TRIAL
For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact Risk Factors Associated with Severe COVID-19 in Eastern France: Analysis of 1045 Cases The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. These preprints are early stage research papers that have not been peer-reviewed. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. Loïc Lefebvre, R&D Expert at Carbody, said: “The strength of this new Technyl Max was instrumental in maximising lightweighting for our unique pedal concept.Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. “It was a great opportunity for us to co-design Skeleton in close partnership with Carbody, demonstrating the performance of our brand new highly-filled Technyl Max.” Gérald Durski, Marketing Director for Solvay’s Performance Polyamides, said: “Automotive OEMs and Tiers are increasingly looking for high rigidity materials to substitute a range of metal components for the lightweighting of new energy vehicles.” This provides the Skeleton brake pedal superior fracture resistance under loads up to 3,000N and even maintains its operational safety beyond that limit. The pedal, named Skeleton, features a rod-shaped composite structure which is over-moulded with 60 per cent glass-filled new Technyl Max technology.